Session 5: Recent Cohort Studies

The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

Coverage provided by Joep Lange, M.D.

June 27, 1999

Changes in body shape and laboratory parameters -- including virologic and immunologic -- were assessed in 106 patients with lipodystrophy who had received a protease inhibitor (PI) for at least 9 months. Fifty-two patients were randomized to d4T + ddI + nevirapine (NVP), while 54 remained on PI therapy. CD4+ cell count and CD4% continued to increase in both groups at 24 weeks, although 2 patients in each arm showed viral rebound. There were no significant improvements in dual energy x-ray absorptiometry scans or anthropometric measurements in either group, although cholesterol and triglyceride levels decreased significantly in the NVP arm.

The triglyceride and cholesterol reductions among patients receiving NVP suggests that PI use is associated with metabolic abnormalities. The fact that these reductions were observed despite the use of d4T + ddI therapy shows that these agents are not major contributors to these metabolic abnormalities. However, the follow up time was short; increased differences may be observed over a longer period of follow up and as more patients are enrolled in the study.

Abstract: A Multicenter, Randomized, Open-Label, Comparative Trial of the Clinical, Immunological and Virological Benefit of Switching the PI Nevirapine in HAART-Experienced Patients Suffering Lipodystrophy
Authored by: L. Ruiz, E. Negredo, A. Bonjoch, R. Paredes, J. Romeu, G. Sirera, R.C. Fumaz, L. Zamora, and B. Clotet for the LD Study Group

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.